Search Results

NanOlogy LLC, a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.

NanOlogy LLC, a clinical-stage oncology company, announces a presentation of clinical research involving its large surface area microparticle investigational drugs at DDW 2023 in May and publication at ASCO Annual Meeting in June.

NanOlogy LLC, a clinical-stage oncology company, announced issuance of a US patent titled: Local Delivery of Antineoplastic Particles in Combination with Systemic Delivery of Immunotherapeutic Agents for the Treatment of Cancer.

NanOlogy LLC announced that initial safety and clinical outcomes from a Phase 2 clinical trial of intratumoral large surface area microparticle paclitaxel in locally advanced pancreatic cancer were published online ahead of print in Pancreas and two posters were presented at the ninth AACR Special Conference on Pancreatic Cancer in Boston reporting downstaging and immune data from the trial.

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced publication of a research article entitled Early Phase Trial of Intracystic Injection of Large Surface Area Microparticle Paclitaxel for Treatment of Mucinous Pancreatic Cysts in Endoscopy International Open.

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel, has been published in Drug Delivery and Translational Research.

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced enrollment is complete in a Phase 2a trial of intratumoral large surface area microparticle paclitaxel with standard of care therapy in patients with nonoperable lung cancer.

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel, has been published in Drug Delivery and Translational Research.

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that results from a clinical trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer have been published in The Journal of Urology®.

Nanology Labs, an IND-stage company developing next generation nanomedicines to conquer cancer, announced that its seed capital raise was oversubscribed at $3M.